Correlating ISEND and Tumor Mutation Burden (TMB) with Clinical Outcomes of Advanced Non-Small Cell Lung Cancer (ANSCLC) Patients on Nivolumab

被引：0
|
作者：
Park, W. [1 ]
Lopes, G. [1 ]
Kwon, D. [2 ]
Florou, V. [1 ]
Chae, Y. K. [3 ]
Warsch, J. [4 ]
Ishkanian, A. [5 ]
Jahanzeb, M. [6 ]
Mudad, R. [1 ]
机构：
[1] Univ Miami, Sylvester Comprehens Canc Ctr, Hematol & Oncol, Miami, FL USA
[2] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Med Biostat & Bioinformat, Miami, FL USA
[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Dev Therapeut Program, Chicago, IL 60611 USA
[4] Univ Miami, Sylvester Comprehens Canc Ctr, Radiol, Miami, FL USA
[5] Univ Miami, Sylvester Comprehens Canc Ctr, Radiat Oncol, Miami, FL USA
[6] Univ Miami, Sylvester Comprehens Canc Ctr, Med Oncol, Miami, FL USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Tumor mutation burden; biomarker; Nivolumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.07-025
引用
收藏
页码：S2004 / S2005
页数：2
相关论文
共 50 条
  • [41] Non-Small Cell Lung Cancer as a Precision Oncology Paradigm: Emerging Targets and Tumor Mutational Burden (TMB)
    Tafe, Laura J.
    ADVANCES IN ANATOMIC PATHOLOGY, 2020, 27 (01) : 3 - 10
  • [42] The Study of Relationship Between Tumor Burden (TMB) and Molecular Typing of Non-Small Cell Lung Cancer (NSCLC)
    Zhong, R.
    Li, H.
    Cheng, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1087 - S1087
  • [43] Outcomes of Nivolumab in Elderly Patients (pts) with Non-Small Cell Lung Cancer (NSCLC)
    Bagley, Stephen
    Kothari, Shawn
    Aggarwal, Charu
    Bauml, Joshua
    Alley, Evan
    Evans, Tracey
    Kosteva, John
    Ciunci, Christine
    Thompson, Jeffrey
    Stonehouse-Lee, Susan
    Sherry, Victoria
    Gilbert, Elizabeth
    Eaby-Sandy, Beth
    Mutale, Faith
    Dilullo, Gloria
    Cohen, Roger
    Vachani, Anil
    Langer, Corey
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1289 - S1289
  • [44] Clinical and Immunological Factors Associated with Mutation Burden in Non-Small Cell Lung Cancer
    Terada, Y.
    Ono, A.
    Isaka, M.
    Kawata, T.
    Serizawa, M.
    Kawabata, T.
    Imai, T.
    Muramatsu, K.
    Hayashi, I.
    Kenmotsu, H.
    Kusuhara, M.
    Akiyama, Y.
    Yamaguchi, K.
    Sugino, T.
    Ohde, Y.
    Takahashi, T.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S724 - S724
  • [45] Alternative Nivolumab (N) Duration and Scheduling in Advanced Non-Small Cell Lung Cancer (aNSCLC): Real-Life Data
    Dudnik, E.
    Moskovitz, M.
    Agbarya, A.
    Kuznetsov, T.
    Shochat, T.
    Urban, D.
    Wollner, M.
    Zer, A.
    Rotem, O.
    Peled, N.
    Bar, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S235 - S236
  • [46] A Dynamic Deep Learning Approach to Predict Clinical Outcomes of Patients with Advanced Non-Small Cell Lung Cancer under Nivolumab Monotherapy
    Lu, S.
    Yang, Y.
    Yang, J.
    Chen, J.
    Xia, L.
    Wang, Y.
    Ge, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S478 - S478
  • [47] Developing a Predictive Clinical Outcome Model for Advanced Non-Small Cell Lung Cancer Patients Receiving Nivolumab
    Park, W.
    Kwon, D.
    Saravia, D.
    Desai, A.
    Warsch, J.
    Vargas, F.
    El Dinali, M.
    Elias, R.
    Chae, Y.
    Kim, D. W.
    Warsch, S.
    Ishkanian, A.
    Ikpeazu, C.
    Mudad, R.
    Lopes, G.
    Jahanzeb, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2429 - S2430
  • [48] Biopsy on progression in EGFR mutation positive (EGFRm) advanced non-small cell lung cancer (aNSCLC) patients (pts): A Canadian experience
    Chu, Q. S-C.
    Agha, A.
    Devost, N. C.
    Walton, R.
    Ghosh, S.
    Ho, C.
    ANNALS OF ONCOLOGY, 2018, 29 : 528 - 528
  • [49] DNA damage response and repair (DDR) gene mutations and correlation with tumor mutation burden (TMB) in non-small cell lung cancer (NSCLC).
    Mamdani, Hirva
    Chen, Jerry
    Kim, Seongho
    Ibrahim, Yahya
    Bin Asad, Mohammad Fahad
    Nieva, Jorge J.
    Feldman, Rebecca
    Naqash, Abdul Rafeh
    Liu, Stephen V.
    Ma, Patrick C.
    Portnoy, David Craig
    Borghaei, Hossein
    Karim, Nagla Fawzy Abdel
    Boumber, Yanis
    Vanderwalde, Ari M.
    Spira, Alexander I.
    Jalal, Shadia Ibrahim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer
    Zaim, Remziye
    Redekop, Ken
    Uyl-de Groot, Carin A.
    TRANSLATIONAL ONCOLOGY, 2022, 20
12345